Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference Today
Based on preliminary, unaudited financial data the company expects toreport total revenue of approximately $39.5 million for the fourth quarter of2007 and approximately $140 million for the full year, in each case at the topend of the company's previously announced projections. Within fourth quarterrevenue of approximately $39.5 million, combined product and service revenueis expected to be approximately $37 million, an increase of 16% over fourthquarter 2006 combined product and service revenue.
A live webcast of Mr. Hrusovsky's presentation can be accessed athttp://www.metameetings.com/webcasts/jpmorgan/healthcare08/. An archivedpresentation will be available for 90 days.
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of leading-edge technologiesenabling researchers in the life sciences industry to create life-saving andenhancing medicines and diagnostic tests more quickly and efficiently. Caliperis aggressively innovating new technology to bridge the gap between in vitroassays and in vivo results and then translating those results into cures forhuman disease. Caliper's portfolio of offerings includes state-of-the-artmicrofluidics, lab automation & liquid handling, optical imaging technologies,and discovery & development outsourcing solutions. For more information pleasevisit www.caliperLS.com.
The statements in this press release regarding Caliper's anticipated totalrevenue for the fourth quarter of 2007 and for 2007 and its expected combinedproduct and service revenue for the fourth quarter of 2007 are "forward-looking statements" within the meaning of Section 21E of the SecuritiesExchange Act of 1934. These statements are subject to risks and uncertaintiesthat could cause actual results to differ materially from those Caliperexpects or projects, including the risks that unexpected information may bereceived, or adjustments may be made, in the course of finalizing andanalyzing the financial results, which could cause the final results to differfrom these preliminary results. Further review of the company's financialresults for 2007 could lead to revisions in the company's current expectationsregarding revenue for this period and the portion of such revenue consistingof combined product and service revenue. Further information on risks faced byCaliper is included in risks discussed under the caption "Risk Factors" inCaliper's annual report on Form 10-K for the year ended December 31, 2006,filed with the Securities and Exchange Commission on March 14, 2007, and inour other SEC reports and filings. These SEC reports and filings are availableon a web site maintained by the SEC at http://www.sec.gov. Caliper expresslydisclaims any obligation or undertaking to release publicly any updates orrevisions to any forward-looking statements contained herein to reflect anychange in Caliper's expectations with regard thereto or any change in events,conditions, or circumstances on which any such statements are based.
Caliper is a registered trademark of Caliper Life Sciences, Inc.
SOURCE Caliper Life Sciences, Inc.
You May Also Like